Breadcrumb

null Marc Rodger, MD, M.Sc.

Senior Scientist, RI-MUHC , 5252 de Maisonneuve

Cardiovascular Health Across the Lifespan Program

Centre for Outcomes Research and Evaluation

Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Hematology, MUHC

 

Keywords


Venous thrombosis • pulmonary embolism • pregnancy • anticoagulation • diagnosis • clinical decision rules • networks

Research Focus


My research focuses on venous thrombosis. I lead multinational randomised trials and cohort studies that seek to change clinical practice in venous thrombosis. This work has been awarded over $38 million in peer-reviewed funding (over $22 million obtained as principal investigator). My team has confirmed a weak link between thrombophilia and placental mediated pregnancy complications. We have conducted trials that showed that blood thinners do not prevent these complications, changing a common practice and sparing many women the need to inject blood thinners daily throughout pregnancy. I derived and validated a tool, “Men continue and HERDOO2,” that is used worldwide to assist in deciding whether to anticoagulate venous thrombosis lifelong, and my team is currently exploring whether an inexpensive and generic cholesterol-lowering drug might reduce the risk of venous thrombosis. I co-founded and co-direct the CIHR-funded CanVECTOR (Canadian Venous Thrombosis Clinical Trials and Outcomes Research) Network (CanVECTOR.ca) and founded the International Network of Venous Thrombosis Clinical Research Networks (INVENT; INVENT-VTE.com).

Selected Publications


Click on Pubmed to see my current publications list

  • Rodger MA, Le Gal G, Anderson DR, et al and for the REVERSE II Study Investigators* Validating the HERDOO2 Rule to Guide Treatment Duration for Women with Unprovoked Venous Thrombosis: A Multi-National Prospective Cohort Management Study. BMJ 2017;365:j1065.

  • Rodger MA, Gris J-C, de Vries JI. Low-molecular-weight heparin does not prevent recurrent placenta-mediated pregnancy complications: an individual patient data meta-analysis of randomized controlled trials Lancet 2016 Nov 26;388(10060):2629-2641.

  • Rodger MA, Hague WM, Kingdom J, et al for the TIPPS Investigators Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial Lancet 2014 Nov 8;384(9955):1673-83.

  • Rodger MA, Walker MC, Smith GN et al. Is thrombophilia associated with placenta-mediated pregnancy complications. A Prospective Cohort Study. J Thromb Haemost 2014;12:469-478.

  • Rodger MA, Kahn SR, Wells PS et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008;179:417-426.